Latest News and Press Releases

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...

Allowance received for the use of SIRPaFc to treat both hematologic and solid tumors (method of use patent)Allowance received for the TTI-622 composition of matter patent CAMBRIDGE, Mass., Oct. 05,...

CAMBRIDGE, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...

CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...

CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...

Pfizer invests $25 million in Trillium common shares at $10.88 per shareJeff Settleman, PhD, Pfizer’s Chief Scientific Officer for Oncology Research & Development, to join Trillium Scientific...

TTI-622 (SIRPa-IgG4 Fc) completed 8 mg/kg safety assessment in the ongoing dose escalation study in relapsed/refractory lymphoma; now escalating to 12 mg/kg dose level.TTI-622 monotherapy shows 6/18...

TTI-621 study has progressed to the 2.0 mg/kg dosing levelTTI-622 showing early evidence of monotherapy activity$130.8 million of cash and investments as of June 30, 2020 CAMBRIDGE, Mass., Aug. ...

CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative...